GC Biopharma said Monday that its immunoglobulin blood product Alyglo (GC5107B, 10-percent intravenous immunoglobulin) has passed the U.S. Food and Drug Administration's preliminary review for marketing authorization.The company added that the U.S. FDA has also initiated the review of GC5107B for fi

https://www.koreabiomed.com/news/articleView.html?idxno=21729

#koreabiomed